Resources Library

In partnership with Alun Bedding, PhD — a consultant and executive coach with 35+ years in pharma leadership — we sat down for a candid Q&A on where clinical development is headed. Alun talks through why Bayesian methods are still misunderstood by sponsors, and what separates the organisations that use them well from those that don't. He also makes the case for keeping patients in the room during trial design, arguing that a trial which finishes recruiting with imperfect statistical power can ultimately serve patients better than a well-powered trial that never completes.

For decades, clinical development leaders in US and Europe have viewed China primarily through a logistical lens: a large patient pool capable of accelerating trial enrolment. However, the industry dynamics are shifting. China has evolved from a destination for increased patient access into a source of novel biomedical innovation [Clinical Leader, 2021], [Armstrong, 2026]. Executives leading biopharmas, CROs and CDMOs must adapt to this transformation to facilitate a bi-directional flow of cross-border innovation.